As a new 13D filing with the SEC has revealed, Julian and Felix Bakers‘ Baker Bros. Advisors amassed a substantial position in the recently public company Beigene Ltd (ADR) (NASDAQ:BGNE). The filing showed that Baker Bros. owns 105.20 million shares of Beigene, which represent some 24.6% of the company’s outstanding stock.
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Baker Bros. Advisors | 105,199,597 | 0 | 105,199,597 | 0 | 105,199,597 | 24.6% |
| Baker Bros. Advisors (GP) | 105,199,597 | 0 | 105,199,597 | 0 | 105,199,597 | 24.6% |
| Felix J. Baker | 105,199,597 | 9. | 105,199,597 | 11. | 105,199,597 | 24.6% |
| Julian C. Baker | 105,199,597 | 9. | 105,199,597 | 11. | 105,199,597 | 24.6% |
Follow Julian Baker And Felix Baker's Baker Bros. Advisors
Page 1 of 10 SEC Filing
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13D
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS
FILED PURSUANT
TO RULE 13d-l(a) AND AMENDMENTS THERETO
FILED PURSUANT
TO RULE 13d-2(a)
(Amendment No. )*
BeiGene, Ltd.
(Name of Issuer)
Ordinary Shares, par value $0.0001 per
share
(Title of Class of Securities)
07725L102**
(CUSIP number)
Alexandra A. Toohey
Chief Financial Officer
Baker Bros. Advisors LP
667 Madison Avenue, 21st Floor
New York, NY 10065
(212) 339-5690
(Name,
address and telephone number of person authorized to receive notices and communications)
February 8, 2016
(Date of event which requires filing of
this statement)
If
the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule
13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box ¨.
(Continued on the following pages)
(Page 1 of 10 Pages)
*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise
subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
**This CUSIP applies to the American Depository Shares, each
representing thirteen Ordinary Shares
Follow Beone Medicines Ltd. (NASDAQ:ONC)
Follow Beone Medicines Ltd. (NASDAQ:ONC)
Receive real-time insider trading and news alerts
